Active Biotech AB (publ)

OM:ACTI Stock Report

Market Cap: SEK 143.9m

Active Biotech Balance Sheet Health

Financial Health criteria checks 3/6

Active Biotech has a total shareholder equity of SEK1.4M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK14.9M and SEK13.5M respectively.

Key information

0%

Debt to equity ratio

SEK 0

Debt

Interest coverage ration/a
CashSEK 6.20m
EquitySEK 1.40m
Total liabilitiesSEK 13.50m
Total assetsSEK 14.90m

Recent financial health updates

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Feb 19
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Jul 27
Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

May 07
Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03
We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18
We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Financial Position Analysis

Short Term Liabilities: ACTI's short term assets (SEK10.7M) do not cover its short term liabilities (SEK11.5M).

Long Term Liabilities: ACTI's short term assets (SEK10.7M) exceed its long term liabilities (SEK2.0M).


Debt to Equity History and Analysis

Debt Level: ACTI is debt free.

Reducing Debt: ACTI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACTI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ACTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.3% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 09:00
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Active Biotech AB (publ) is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Stefan WaldenlindCarnegie Investment Bank AB
Thomas BowersDanske Bank